On February 11, 2020, the manufacturer voluntarily withdrew the product from the European Union market. References
External links
"Ingenol mebutate". Drug Information Portal. U.S. National Library of Medicine.
Diagnosis
Electrocardiographic features include:
Atrial rate: 100 to 250 BPM
Ventricular conduction can be variable
Irregular or irregularly irregular in the setting of variable AV block
Regular if 1 to 1, 2 to 1, or 4 to 1 AV block
P wave morphology
Unifocal, but similar in morphology to each other
Might be inverted
Differs from normal sinus P wave
May exhibit either long RP or short PR intervals
Rhythm may be paroxysmal or sustained
May demonstrate an increase in the rate at initiation (e.g., "warm up," or "rev up")
May demonstrate a decrease in the rate at termination (e.g., "cool down")

Treatment
Initial management of focal atrial tachycardia should focus on addressing underlying causes: treating acute illness, cessation of stimulants, stress reduction, appropriately managing digoxin toxicity, or chronic disease management. The ventricular rate is controllable with the use of beta blockers or calcium channel blockers. If atrial tachyarrhythmia persists and the patient is symptomatic, the patient may benefit from class IA, IC, or class III antiarrhythmics. Catheter ablation of focal atrial tachycardia may be appropriate in patients failing medical therapy. Epidemiology
A European study of young males applying for pilot licenses demonstrated that 0.34% had asymptomatic atrial tachycardia and 0.46% had symptomatic atrial tachycardia. References


== External links ==